SynthesisRespiratory research2019
Efficacy and safety of dupilumab for the treatment of uncontrolled asthma: a meta-analysis of randomized clinical trials.
Synthesis in Respiratory research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The efficacy and safety of biologics for patients with severe asthma: an umbrella review of systematic reviews and meta-analyses.Frontiers in medicine · 2025Pooled it
- Dupilumab efficacy and safety in patients with moderate to severe asthma: A systematic review and meta-analysis.Frontiers in pharmacology · 2022Pooled it
- NAVIGATOR: a phase 3 multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of tezepelumab in adults and adolescents with severe, uncontrolled asthma.Respiratory research · 2020Trial
- Severe Asthma and Biological Therapies: Now and the Future.Journal of clinical medicine · 2023Review
- Real-world evidence for the effectiveness and safety of dupilumab in patients with CRSwNP after 1 year of therapy.The World Allergy Organization journal · 2023Article
- Effectiveness and economic impact of Dupilumab in asthma: a population-based cohort study.Respiratory research · 2023Article
- β-Arrestin-biased proteinase-activated receptor-2 antagonist C781 limits allergen-induced airway hyperresponsiveness and inflammation.British journal of pharmacology · 2023Article
- Baseline Demographics and Severity and Burden of Atopic Dermatitis in Adult Patients Initiating Dupilumab Treatment in a Real-World Registry (PROSE).Dermatology and therapy · 2022Article
- Effectiveness and safety of dupilumab in patients with chronic rhinosinusitis with nasal polyps and associated comorbidities: a multicentric prospective study in real life.Clinical and molecular allergy : CMA · 2022Article
- Pathophysiology of Dysphagia in Eosinophilic Esophagitis: Causes, Consequences, and Management.Digestive diseases and sciences · 2022Review
- Effect of Dupilumab in Korean Patients With Uncontrolled Moderate-to-Severe Asthma: A LIBERTY ASTHMA QUEST Sub-analysis.Allergy, asthma & immunology research · 2022Article
- Early effectiveness of type-2 severe asthma treatment with dupilumab in a real-life setting; a FeNO-driven choice that leads to winning management.Multidisciplinary respiratory medicine · 2022Article
- Critical evaluation of asthma biomarkers in clinical practice.Frontiers in medicine · 2022Review
- Severe asthma: adding new evidence - Latin American Thoracic Society.ERJ open research · 2021Review
- Anti-alarmins in asthma: targeting the airway epithelium with next-generation biologics.The European respiratory journal · 2020Review
- Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option?Respiratory research · 2020Review
- CASCADE: a phase 2, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the effect of tezepelumab on airway inflammation in patients with uncontrolled asthma.Respiratory research · 2020Article
- Efficacy and Safety of Biologic Agents in Chronic Urticaria, Asthma and Atopic Dermatitis - A Real-life Experience.The open respiratory medicine journal · 2020Article
- Eosinophilic Gastritis in a Patient Previously Treated with Dupilumab.Case reports in gastrointestinal medicine · 2020Article
- Severe Eosinophilic Asthma.Journal of clinical medicine · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSeveral recent clinical trials have assessed the effects of dupilumab in uncontrolled asthma, but reached no definite conclusion. We therefore conducted this meta-analysis to evaluate the overall efficacy and safety of dupilumab for the treatment of uncontrolled asthma.
methodsAll randomized controlled trials were included. Standard mean differences (SMD) or relative risks (RR) were calculated using Fixed-or random-effects models.
resultsFive studies involving 3369 patients were identified. Pooled analysis showed significant improvements in the first-second forced expiratory volume (FEV
conclusionDupilumab treatment is relatively well-tolerated and could significantly improve FEV
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.